RespireRx Pharmaceuticals Inc (RSPI)

[Running Q]

That’s not how valuation works. A financing arrangement like the once detailed in the PR will definitely favor the lender but the .02 conversion rate isn’t a valuation determinant of the company. Basically this got them another year of operating expenses to further the various Phase studies.

Ideally, they receive FDA approval along the way for one of their treatments and are bought out by a major pharmaceutical company. The longer it takes the more deals like this will be done thereby increasing the O/S which in turn decreases shareholder value. For investors its like a race against the clock and the major risk is how high will the O/S get before FDA approval and profitable viability can be shown.

I’m confident in my DD and holdings. The pps could stagnate in the .04-.05 range for months, could suddenly spike to a $1.00+ with news of positive results and FDA approval (especially if the O/S stays in the low 100 millions) or it could take more years and more dilution and the pps drifts back down to the sub .01 range...Only time will tell. My money is on the middle scenario.